Results 211 to 220 of about 67,365 (299)

Inhibition of peripheral CB1 receptors modulates food intake and metabolic efficiency in obesity independently of the gut–brain vagal axis

British Journal of Pharmacology, EarlyView.
Background and Purpose Obesity involves profound disruptions in neuronal circuits, neuroendocrine communication and the endocannabinoid system. While global blockade of cannabinoid CB1 receptors improves metabolism, its clinical use is limited by neuropsychiatric side effects.
Oriane Onimus, Camille de Almeida, Benoit Bertrand, Julien Castel, Nejmeh Mashhour, Anthony Ansoult, Serge Luquet, Giuseppe Gangarossa   +7 more
wiley   +1 more source

Sustained Action of Imapextide, A Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy Volunteers.

J Clin Endocrinol Metab
Fabbrini E, Koshkina A, Hackett M, Zhao M, Thalluri K, Hompesch M, Macias A, Schneider K, D'Alessio DA, DiMarchi RD, Azoulay S.   +10 more
europepmc   +1 more source

The Association Between Glucagon-like Peptide-1 Receptor Agonists and Clinical Outcomes in Patients with Thoracic Aortic Aneurysm. [PDF]

Diagnostics (Basel)
Raslan MA, Abdul Nabi H, Dreher L, Al Osta S, De Sousa Barzon Serra V, Ayoub C, El Masry H, Shamoun FE.   +7 more
europepmc   +1 more source

Multivalent antibody‐based conjugates as new tools for tailored modulation of G protein–coupled receptors

British Journal of Pharmacology, EarlyView.
The G protein–coupled receptor (GPCR) superfamily consists of the most common targets of approved drugs. Targeting GPCRs offers appealing avenues for therapeutic development. Antibodies and their fragments, such as single‐domain antibodies (VHHs or nanobodies), have emerged as useful alternatives to small molecule pharmacophores as building blocks in ...
Shivani Sachdev, Ross W. Cheloha
wiley   +1 more source

Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists [PDF]

John W. Ostrominski, Scott D. Solomon, Muthiah Vaduganathan   +2 more
openalex   +1 more source

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

Glucagon-like Peptide-1 Receptor Agonists and Anaesthesia Considerations

Airway
Hemlata Kapoor, Dheeraj Kapoor
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists in Obesity-Induced Respiratory Pathophysiology. [PDF]

Acta Physiol (Oxf)
Ruiz MA, Furquim THDC, Davaanyam D, Williams NR, Polotsky VY, Amorim MR.   +5 more
europepmc   +1 more source

Association of glucagon‐like peptide‐1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes

Yuting Yu, Ying Chun Lee, Yu-Wei Fang, Wen-Hui Hsieh, Ming-Hsien Tsai   +4 more
openalex   +1 more source

Vision impairment following glucagon-like peptide-1 receptor agonist use: is it harmful? [PDF]

Maria Cecilia Bahit, Michael K. Gibson, Martyna Kuleta, Łukasz Szarpak, Krzysztof Piotr Malinowski, Iwona Kowalska‐Bobko, Zbigniew Siudak   +6 more
openalex   +1 more source